Canopy Growth’s Clock Is Ticking: Two Washington Catalysts Meet a Nasdaq Deadline
Published on 07/23/2026 at 19:13 | Redaktion boerse-global.de
The Canadian cannabis producer is navigating a rare convergence of regulatory and legislative momentum in the United States, yet the stock remains pinned near its 52-week low. Canopy Growth shares edged up 0.7% to €0.8006 on Thursday, a modest gain that does little to mask the 17.86% gap below the 200-day moving average of €0.9747. With the 52-week trough of €0.7500 sitting just 6.75% below the current price, the margin for error is razor-thin.
DEA Hearings Conclude, Senate Bill Reappears
The formal hearing phase of the Drug Enforcement Administration’s review into cannabis rescheduling ended on July 15, 2026. Witness testimony on medical efficacy and safety profiles has been completed, shifting the focus to the next procedural milestone: all parties must file their closing submissions by August 17, 2026. An administrative law judge will then issue a recommendation, the last formal hurdle before a final federal decision on rescheduling.
That DEA process is running in parallel with a fresh legislative push. On July 22, 2026, 17 U.S. senators reintroduced the Cannabis Administration and Opportunity Act, with Majority Leader Chuck Schumer and Senator Cory Booker among the sponsors. The bill would remove marijuana entirely from the federal controlled substances list and establish a comprehensive regulatory framework. Earlier versions stalled in Congress, but the timing — immediately after the DEA hearings concluded — has reignited speculation among investors. Canadian producers with U.S. exposure, including Canopy Growth through its non-consolidated stake in Canopy USA, are seen as direct beneficiaries of any federal liberalization.
Tax Relief Already Flowing
While the legislative drama unfolds, a more concrete financial benefit is already in place. The reclassification of medical cannabis to the less restrictive Schedule III category took effect in April 2026, fundamentally altering Canopy Growth’s tax burden. Previously, Section 280E of the U.S. tax code prohibited cannabis companies from deducting ordinary business expenses such as rent, utilities, and marketing. With the new classification, Canopy Growth can now claim those deductions for its medical segment — a division that reported 27% revenue growth in the fourth quarter of fiscal 2026, which ended March 31.
Should investors sell immediately? Or is it worth buying Canopy Growth?
The tax relief is expected to directly strengthen cash flow, with management targeting positive adjusted EBITDA as the next milestone.
Balance Sheet and Deal Integration
Canopy Growth closed fiscal 2026 with a net cash position of approximately $131.3 million, achieved through a strategic recapitalization earlier in the year. The company also completed the acquisition of MTL Cannabis in June 2026, positioning itself as Canada’s largest medical cannabis provider by revenue.
The loss per share narrowed sharply to C$0.40 in the latest quarter, compared with C$1.43 in the same period a year earlier, though weaker segments like Storz & Bickel continue to weigh on overall performance.
Canopy Growth at a turning point? This analysis reveals what investors need to know now.
Two Key August Dates
Investors have two events circled on the calendar. On August 7, 2026, Canopy Growth will report fiscal first-quarter 2027 results, marking the first full quarter reflecting the Schedule III tax benefit and initial contributions from the MTL integration. Four days later, on August 11, CEO Luc Mongeau will present at the Canaccord Genuity Growth Conference in Boston, where he is expected to outline a sharper U.S. strategy and the path to profitability.
Nasdaq Compliance Looms
The stock’s persistent weakness below $1.00 — the minimum bid price required for continued listing on the Nasdaq Global Select Market — remains a structural overhang. The company has used reverse stock splits in the past to meet the exchange’s requirements, and the market is bracing for the possibility of further corporate actions if a sustained rally fails to materialize. For now, Canopy Growth is betting that Washington’s dual-track reform effort can lift the stock before the exchange’s patience runs out.
Ad
Canopy Growth Stock: New Analysis - 23 July
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
